A quick translation. DNA methylation does not rewrite the genetic code. It acts more like editorial markup on top of it. Same script, different stage directions. In cancer, those stage directions can get weird fast.
The investigators analyzed tumor samples taken before immune checkpoint inhibitor treatment from 91 patients with pleural mesothelioma in the retrospective multicenter NIBIT-EPI-MESO study.[1] They found four methylation subtypes, arranged along a spectrum of increasing global methylation: demethylated, LOW, intermediate, and CIMP, which stands for CpG island methylator phenotype. Cancer biologists do love an acronym that sounds like a failed energy drink.
And these subtypes were not just molecular trivia. They tracked with response to immunotherapy and survival.
The standout was the LOW subtype. Those tumors were enriched in patients who responded to treatment, had the longest median overall survival, and showed a microenvironment rich in T cells and B cells.[1] In plain English: the immune system had actually shown up to work.
At the other end sat CIMP, the subtype enriched in nonresponders, with the shortest survival and a more depleted immune microenvironment.[1] That is the immunotherapy version of showing up to a bar fight and discovering your bouncer called in sick.
Why This Matters More Than Another Fancy Heatmap
Pleural mesothelioma is rare, aggressive, and still deeply rude. Immunotherapy changed the landscape, especially after CheckMate 743 established nivolumab plus ipilimumab as a first-line standard for unresectable disease.[2] But "changed the landscape" is not the same as "solved the problem." In the 5-year CheckMate 743 follow-up published in March 2026, 5-year overall survival was still only 14% with nivolumab plus ipilimumab versus 6% with chemotherapy.[2] Better, yes. Good enough, absolutely not.
That is the gap this paper tries to close.
Right now, mesothelioma lacks a reliable biomarker that tells you who is likely to benefit from checkpoint blockade. PD-L1 has been about as consistently helpful as a smoke alarm with low batteries.[3,6] So the appeal here is obvious: if methylation patterns can flag the patients with an immune-ready tumor versus an immune-desert tumor, treatment choices could get a lot less guessy.
The authors also built a methylation-based probabilistic classification tool to predict immunotherapy outcome.[1] That is not the same thing as a clinic-ready test next Monday morning, but it is a serious step toward one.
The Bigger Biology Mess, Now Slightly Less Messy
This paper also fits with a growing picture of mesothelioma as a disease shaped not just by mutations, but by immune architecture and epigenetics. A 2023 Nature Genetics multiomic study showed that pleural mesothelioma heterogeneity is driven by multiple axes, including adaptive immune response and CpG island methylator profile, not just classic histology.[5] A 2025 study in Journal of Experimental & Clinical Cancer Research further linked DNA methylation status in mesothelioma cells to immune behavior, suggesting epigenetic states may help create either a welcoming neighborhood for immune cells or a locked compound with bad lighting and worse intentions.[4]
That matters because immunotherapy does not kill tumors by magic. It works best when immune cells can recognize the threat, enter the tumor, and keep functioning once inside. If methylation helps shape that whole setup, then it is not just a biomarker story. It may become a treatment story too. Maybe you do not just read the methylation state. Maybe one day you try to change it.
Careful, though. This is still retrospective work. Ninety-one patients is respectable in mesothelioma, which is not exactly a common cold, but it is still a limited cohort.[1] The classifier needs prospective validation. It also needs to prove it can survive the usual journey from elegant paper to messy real-world clinic, where samples are imperfect, patients are heterogeneous, and biology enjoys humiliating our certainty.
Still, this is the kind of paper that makes an oncologist put down the coffee and reread the figure legend. Not because it promises a miracle. Because it offers something rarer and more useful: a plausible way to make immunotherapy less blind.
References
-
Calabrò L, Caruso FP, Covre A, et al. Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study. Nature Genetics. 2026. DOI: 10.1038/s41588-026-02580-4
-
Scherpereel A, Baas P, Nowak AK, et al. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. Journal of Clinical Oncology. 2026;44(9):742-749. DOI: 10.1200/JCO-25-01328
-
Calabrò L, Bronte G, Grosso F, et al. Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream. Frontiers in Immunology. 2024;14:1333661. DOI: 10.3389/fimmu.2023.1333661 | PMCID: PMC10800748
-
Lofiego MF, Tufano R, Bello E, et al. DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy. Journal of Experimental & Clinical Cancer Research. 2025;44:58. DOI: 10.1186/s13046-025-03310-0
-
Mangiante L, Alcala N, Sexton-Oates A, et al. Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity. Nature Genetics. 2023;55:607-618. DOI: 10.1038/s41588-023-01321-1
-
Delsignore M, Cassinari G, Revello S, et al. Determinants of Response to Immune Checkpoint Blockade in Pleural Mesothelioma: Molecular, Immunological, and Clinical Perspectives. Cancers (Basel). 2025;17(24):4020. DOI: 10.3390/cancers17244020 | PMCID: PMC12731717
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.